Freya Biosciences secures new investment to develop microbial immunotherapies for bacterial vaginosis

Freya BiosciencesNov 25 2024 Freya Biosciences , a transatlantic biotech company specializing in women's health, today announces a $10.4 million strategic investment from the Bill & Melinda Gates Foundation with $1.4 million additional financing from current investor Export and Investment Fund of Denmark .

Freya is developing microbial immunotherapies to regulate the immune system and inflammatory responses in the vaginal tract using its DYSCOVER™ platform. Freya has identified Lactobacillus strains that are capable of engrafting in the vaginal tract thereby displacing the existing dysbiotic vaginal microbiome and reducing key inflammation biomarkers. To date the platform has yielded Freya’s lead candidate, FB301 for improving pregnancy success in IVF.

BV is a critically underserved condition, with prevalence among women of reproductive age between 23–29% and higher rates in certain low-and middle-income countries. Women in these regions face disproportionately high risks of preterm birth and associated complications, underscoring the global need for effective, accessible treatments.

Россия Последние новости, Россия Последние новости

Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей

ESG Mining Company Index: The true numbers of women in mining and company boardroomsIndustry still has much to do to achieve true equality
Источник: MiningOnline - 🏆 117. / 51 Прочитайте больше »